EP Patent

EP3554489A1 — Treatment of moderate and severe gastroparesis

Assigned to Evoke Pharma Inc · Expires 2019-10-23 · 7y expired

What this patent protects

Metoclopramide is administered for the treatment of moderate to severe gastroparesis, in some embodiments, severe gastroparesis.

USPTO Abstract

Metoclopramide is administered for the treatment of moderate to severe gastroparesis, in some embodiments, severe gastroparesis.

Drugs covered by this patent

Reglan (Metoclopramide Hydrochloride) · Hikma

Patent Metadata

Patent number: EP3554489A1
Jurisdiction: EP
Classification: —
Expires: 2019-10-23
Drug substance claim: No
Drug product claim: No
Assignee: Evoke Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.